US brain-computer-interface startup Paradromics is quickly establishing itself as a major player in the neural-device space, with the Food and Drug Administration (FDA) green-lighting a human trial to test its ability in restoring speech in people with paralysis. The Austin-based…
Continue reading with a subscription
This article is available to subscribers. Subscribe to read it in full, or sign in if you already have an account.